Sistema de Salut de Catalunya
Institut Català de la Salut
[Morote J, Celma A] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Cirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Picola N] Servei d’Urologia, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain. [Muñoz-Rodriguez J] Servei d’Urologia, Hospital Universitari Parc Taulí, Sabadell, Spain. [Paesano N] Clínica Creu Blanca, Barcelona, Spain. [Ruiz-Plazas X] Servei d’Urologia, Hospital Universitari Joan XXIII, Tarragona, Spain. [Muñoz-Rivero MV] Servei d’Urologia, Hospital Arnau de Vilanova, Lleida, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-10-05T07:47:08Z
2023-10-05T07:47:08Z
2023-09-13
Prostate biopsy concordance; Systematic biopsy; Targeted biopsy
Concordancia de biopsia de próstata; Biopsia sistemática; Biopsia dirigida
Concordança de biòpsia de pròstata; Biòpsia sistemàtica; Biòpsia dirigida
The primary objective of this study was to analyse the current accuracy of targeted and systematic prostate biopsies in detecting csPCa. A secondary objective was to determine whether there are factors predicting the finding of csPCa in targeted biopsies and, if so, to explore the utility of a predictive model for csPCa detection only in targeted biopsies. We analysed 2122 men with suspected PCa, serum PSA > 3 ng/mL, and/or a suspicious digital rectal examination (DRE), who underwent targeted and systematic biopsies between 2021 and 2022. CsPCa (grade group 2 or higher) was detected in 1026 men (48.4%). Discrepancies in csPCa detection in targeted and systematic biopsies were observed in 49.6%, with 13.9% of csPCa cases being detected only in systematic biopsies and 35.7% only in targeted biopsies. A predictive model for csPCa detection only in targeted biopsies was developed from the independent predictors age (years), prostate volume (mL), PI-RADS score (3 to 5), mpMRI Tesla (1.5 vs. 3.0), TRUS-MRI fusion image technique (cognitive vs. software), and prostate biopsy route (transrectal vs. transperineal). The csPCa discrimination ability of targeted biopsies showed an AUC of 0.741 (95% CI 0.721–0.762). The avoidance rate of systematic prostate biopsies went from 0.5% without missing csPCa to 18.3% missing 4.6% of csPCa cases. We conclude that the csPCa diagnostic accuracy of targeted biopsies is higher than that of systematic biopsies. However, a significant rate of csPCa remains detected only in systematic biopsies. A predictive model for the partial omission of systematic biopsies was developed.
This research was funded by the Instituto de Salut Carlos III (SP) and the European Union, grant number PI20/01666.
Article
Published version
English
Pròstata - Càncer - Diagnòstic; Biòpsia; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy; DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms; Other subheadings::Other subheadings::/diagnosis; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::técnicas citológicas::citodiagnóstico::biopsia; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata; Otros calificadores::Otros calificadores::/diagnóstico
MDPI
Cancers;15(18)
https://doi.org/10.3390/cancers15184543
info:eu-repo/grantAgreement/ES/PEICTI2021-2023%2FPI20%2F01666
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
